Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
As últimas notícias da Dr. Falk Pharma
Bem-vindo à nossa Sala de Imprensa que fornece as últimas notícias, comunicados de imprensa, anúncios de ensaios clínicos, eventos e muito mais da Dr. Falk Pharma.
Siga-nos no LinkedIn!
EASL 2025
Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
Today is World Liver Day!
Did you know that our first product back in 1960 was a therapeutic drug for the liver?
Following the footsteps of our founder - The End
Elena looks back and summarizes her journey: it's a collection of emotional encounters, funny moments, and, most of all, it's a big THANK YOU!
Back to the Future – Unleashing the Power of Established Drugs
Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin
Elena em Portugal
... onde se encontrou com o Prof. Dr. Fernando J. Magro Dias no Porto.
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
UEG Week 2024
We look forward to seeing you on booth 46 in Vienna from October 12 – 15, 2024!
Seguindo os passos do nosso fundador
A neta de Herbert Falk, Elena, decidiu seguir os passos do avô. Porquê? Saiba mais e siga a Elena na sua viagem.
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
Hoje é o Dia Mundial da DII!
Teste os seus conhecimentos e saiba mais sobre a DII
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
3000 LinkedIn-Followers!
Thank you very much!
Together we know more. Together we do more.
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
International Liver Congress™ in London
We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!
Digestive Disease Week® 2022
We look forward to 2 exciting presentations on day 4 of this year’s DDW!
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
Resposta à crise da Ucrânia
A Dr. Falk Pharma apoia a APOTHEKER HELFEN e.V.
O futuro começa aqui
Planos concluídos para o futuro Falk Campus em Freiburgo
Together we advance PR600
Investigational New Drug Application for PR600 expected in 3Q 2022.